WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.
The Value of Lepidic and Invasion Patterns New Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma

The Value of Lepidic and Invasion Patterns New Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma

2024.01.19
At the 2023 World Conference on Lung Cancer (WCLC), Dr. Xie Huikang from Shanghai Pulmonary Hospital presented a study titled " The Value of Lepidic and Invasion Pattern NEW Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma ." The study aimed to explore whether the new IASLC definitions and standards had an impact on the diagnosis of AIS, MIA, and IAC compared to previous criteria.
WCLC Voice of China | Dr. Liang Application of Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer

WCLC Voice of China | Dr. Liang Application of Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer

2024.01.19
From September 9th to 12th, 2023, the World Conference on Lung Cancer (WCLC) was held in Singapore. Oncology Frontier deeply engaged in the conference, capturing the latest advancements and witnessing the progress and strides made by China in the international oncology arena. Dr. Liang Hengrui of the First Affiliated Hospital of Guangzhou Medical University presented the results from Chinese researchers in the field of "Artificial Intelligence Application in Thoracoscopic Lobectomy for Lung Cancer" in a brief oral report at the 2023 WCLC.
WCLC 2023| Dr. Wang Jie Awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Award

WCLC 2023| Dr. Wang Jie Awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Award

2024.01.19
The International Association for the Study of Lung Cancer (IASLC) annually presents several awards to clinical physicians and researchers who have made significant contributions to the treatment of lung cancer patients. Awardees are invited to receive their awards at the World Conference on Lung Cancer (WCLC) and give speeches in their respective fields. At the WCLC 2023 conference, these awards were presented for the first time in a dedicated plenary session titled "Plenary Session 2: IASLC Lectureship Award Presentations," jointly hosted by IASLC CEO Karen Kelly and IASLC President Heather Wakelee. The Lectureship awards are presented to members from various fields, including radiation oncology, medical oncology, small cell lung cancer, nursing/health, translational research, thoracic surgery, staging, and tobacco control. Dr. Wang Jie from the Cancer Hospital Chinese Academy of Medical Sciences was awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Lectureship Award for her outstanding contributions to small cell lung cancer research and treatment.
WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology. At the WCLC conference, " Oncology Frontier" invited Dr. Han Baohui, Zhong Runbo, Zhang Wei, and Lu Jun from the affiliated Thoracic Hospital of Shanghai Jiao Tong University School of Medicine to engage in discussions on hot topics at the conference and important clinical research.
WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

2024.01.19
The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with " Oncology Frontier ," Dr. Shi Meiqi shared research insights, key results, and treatment strategies for KRAS mutation non-small cell lung cancer patients.
WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo. On the first day, Dr. Chen Haiquan, Director of the Lung Cancer Research Center at Fudan University and Chief of Thoracic Surgery at Fudan University Affiliated Tumor Hospital, gave an important presentation. During an interview with "Oncology Frontier", Dr. Chen Haiquan shared the key points of his presentation.
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

2024.01.19
The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.
WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.
WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference. Here are the highlights: